The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-02 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Variations in δD of different water sources and ice caps are observed due to evaporation and condensation processes. (See section 6 for more details.) When seawater is well-mixed, the δD at equilibrium is near 0‰ (‰ SMOW) with a DHR of 155.76 ppm. However, continuous variations in δD are caused by evaporation or precipitation processes which lead to disequilibrium in fractionation processes. A large HIC gradient occurs in surface waters of the oceans, and the fluctuation value in the Northwest Atlantic surface water is around 20‰. According to the data examining the southern supersegment of the Pacific Ocean, as latitude decreases from 65˚S to 40˚S, δD fluctuates between around −50‰ and −70‰. The HIC of seawater (not just surface water) is mostly in the range of 0‰ to −10‰. The estimates of δD for different parts of the ocean across the world are shown on the map.
=== Cannabis === Ford supports allowing licensed private retailers to sell cannabis, rather than a government monopoly like the LCBO. Ford opposed the legalization of recreational cannabis. On January 22, 2019, Huffington Post reported that Ford's youngest daughter Kyla, a bodybuilder and fitness trainer, had posted videos promoting health benefits of CBD oil, a cannabis product which typically does not contain the psychoactive compound present in marijuana. Various publications claimed Kyla's promotion wasn't lawful. Ford's daughter took down the posts, but neither Ford nor his daughter commented on them.
After many and long negotiations, the companies came to the agreement to compensate Coulter for the sales that had been made in USA and some European countries where he had the patent and that AB Lars Ljungberg & Co was free to sell their analyzer in other regions.
A further way of carrying out glycosylation is by using enzymes, known as chemo-enzymatic glycosylation. This method is used for complex chemical synthesis. Chemical and chemo-enzymatic methods can be used for the synthesis of glycopeptides and glycoproteins. Cyclization can also be used as a method to decrease proteolytic degradation and prolong half-life, to make the peptide conformation more rigid to hinder enzymatic cleavage. This method can however lead to loss of biological function due to the reduced flexibility making the peptide inactive. For example, side chain to side chain cyclization between asparagine (position 8) and lysine (position 12), of a growth regulating factor (GRF) analogue was found to increase the half-life from 17 minutes to more than 2 hours. Another way to extend half-life do is to bind serum albumin to the peptide. Human serum albumin is the most abundant plasma protein with a molecular weight of 66.4 kDa, and it is involved in many essential bodily functions to maintain homoeostasis. As a result, albumin binding would significantly increase the molecular weight of the peptide, restricting it from being filtered into the urine by the GBM. Serum albumin has an extraordinary long half-life of 2–4 weeks which is much longer than other plasma proteins, due to it binding to the neonatal Fc receptor (FcRn). Fc receptors are proteins found on the surface of certain cells that help to protect the functions of the immune system, by binding to the Fc region of antibodies, which attach to pathogens and destroy them.
Controlled animal and human studies showed that caffeine (energy drinks) in combination with alcohol increased the craving for more alcohol more strongly than alcohol alone. These findings correspond to epidemiological data that people who consume energy drinks generally showed an increased tendency to take alcohol and other substances.
Sources: en.wikipedia.org
== Problems of modernity == In his 1982 book Volksgenossen und Gemeinschaftsfremde (National Comrades and Community Aliens), Peukert argued that the Nazi regime's:"racism offered a model for a new order in society...It rested on the racially legitimated removal of all elements that deviated from the norm, refractory youth, idlers, the asocial, prostitutes, homosexuals, people who were incompetent or failures at work, the disabled. National Socialist eugenics...laid down criteria of assessment that were applicable to the population at whole". Peukert described the aim of National Socialism as:“The goal was an utopian Volksgemeinschaft, totally under police surveillance, in which any attempt at nonconformist behaviour, or even any hint or intention of such behaviour, would be visited with terror”. At the same time, Peukert argued that the völkisch ideology was not "an inexplicable, sudden appearance of 'medieval barbarism' in a progressive society" but rather "demonstrated with heightened clarity and murderous consistency, the pathologies and seismic fractures of the modern civilizing progress". Peukert's thesis that all aspects of the National Socialist regime reflected the völkisch ideology and that far from being a break with modernity, that the National Socialism regime represented at very least an aspect of modernity was very novel at the time and proved to be influential on the historiography of Nazi Germany.
Thrombocytopenia, typically multifactorial, is due to alcoholic marrow suppression, sepsis, lack of folate, platelet sequestering in the spleen, and decreased thrombopoietin. However, this rarely results in a platelet count < 50,000/mL. Aminotransferases AST and ALT are moderately elevated, with AST > ALT. However, normal aminotransferase levels do not preclude cirrhosis. Alkaline phosphatase – slightly elevated but less than 2–3 times the upper limit of normal. Gamma-glutamyl transferase – correlates with AP levels. Typically, much higher in chronic liver disease from alcohol. Bilirubin levels are normal when compensated, but may elevate as cirrhosis progresses. Albumin levels fall as the synthetic function of the liver declines with worsening cirrhosis, since albumin is exclusively synthesized in the liver. Prothrombin time increases, since the liver synthesizes clotting factors. Globulins increase due to shunting of bacterial antigens away from the liver to lymphoid tissue. Serum sodium levels fall (hyponatremia) due to inability to excrete free water resulting from high levels of ADH and aldosterone. Leukopenia and neutropenia are due to splenomegaly with splenic margination. Coagulation defects occur, as the liver produces most of the coagulation factors; thus, coagulopathy correlates with worsening liver disease. Glucagon is increased in cirrhosis. Vasoactive intestinal peptide is increased as blood is shunted into the intestinal system because of portal hypertension.
A tablet of micronized progesterone which is marketed under the brand name Luteina is indicated for sublingual administration in addition to vaginal administration and is available in Poland and Ukraine. A progesterone suppository which is marketed under the brand name Cyclogest is indicated for rectal administration in addition to vaginal administration and is available in Cyprus, Hong Kong, India, Malaysia, Malta, Oman, Singapore, South Africa, Thailand, Tunisia, Turkey, the United Kingdom, and Vietnam. An aqueous solution of progesterone complexed with β-cyclodextrin for subcutaneous injection is marketed under the brand name Prolutex in the Czech Republic, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Switzerland. A non-systemic topical gel formulation of progesterone for local application to the breasts to treat breast pain is marketed under the brand name Progestogel and is available in Belgium, Bulgaria, Colombia, Ecuador, France, Georgia, Germany, Hong Kong, Lebanon, Peru, Romania, Russia, Serbia, Switzerland, Tunisia, Venezuela, and Vietnam. It was also formerly available in Italy, Portugal, and Spain, but was discontinued in these countries. A progesterone intrauterine device was previously marketed under the brand name Progestasert and was available in Canada, France, the United States, and possibly other countries, but was discontinued. Progesterone vaginal rings are marketed under the brand names Fertiring and Progering and are available in Chile, Ecuador, and Peru.
Boat troop – specialists in maritime skills including diving using rebreathers, using kayaks (canoes) and rigid-hulled inflatable boats and often train with the Special Boat Service. Air troop – experts in free fall parachuting and high-altitude parachute operations including High-Altitude Low Opening (HALO) and High-Altitude High Opening (HAHO) techniques. Mobility troop – specialists in using vehicles and are experts in desert warfare. They are also trained in an advanced level of motor mechanics to field-repair any vehicular breakdown. Mountain troop – specialists in Arctic combat and survival, using specialist equipment such as skis, snowshoes and mountain climbing techniques. In 1980 R Squadron (which has since been renamed L Detachment) was formed; its members are all ex-regular SAS regiment soldiers who have a commitment to reserve service. 22 SAS squadron duty rotations are set up as such that one squadron is maintained on Counter-Terrorism duty in the UK; a second will be on a deployment; a third will be preparing for deployment whilst conducting short term training; and the fourth will be preparing for long-term overseas training such as jungle or desert exercises. In times of war, such as the 2003 invasion of Iraq, it is not uncommon for two squadrons to be deployed.
Astrocytes help form the physical structure of the brain, and are thought to play a number of active roles, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier. The concept of a tripartite synapse has been proposed, referring to the tight relationship occurring at synapses among a presynaptic element, a postsynaptic element, and a glial element.
Sources: en.wikipedia.org
== Current research == New treatments and clinical trials for breast cancer patients, non-small cell lung cancer patients, and patients with high grade gliomas or other solid tumors with leptomeningeal disease are currently being explored. People with leptomeningeal metastasis are generally excluded from clinical trials, thereby limiting the systematic assessment of novel therapies in this subgroup of patients with poor prognosis. More patients with leptomeningeal metastasis should be enrolled into trials investigating novel agents with the potential to penetrate the blood–brain barrier. Novel approaches are being studied as currently available therapies are toxic and provide limited benefits.
=== Diagnosis === There are no formal diagnostic criteria for UCTD. It is determined by a differential diagnosis. Diagnostic tests are undertaken to determine whether a patient has a disease assured or undifferentiated of the connective tissues. Patients with UCTD usually have positive ANA (antinuclear antibody), and raised ESR (erythrocyte sedimentation rate) values, without typical autoantibody specificities. Some 20% of the general population, and up to 15% of completely healthy people, test positive for ANA, but this is regarded by some as almost always a sign of an autoimmune disorder. If more specific types of ANAs or other proteins are present, other autoimmune conditions (not UCTD) are implied. Other mechanisms that may be used are tests for Anti-histone antibodies, Chromatin and vitamin D, and chest X-ray to show signs of pericardial effusion.
This activity might explain why kratom can be dangerous when used in combination with other sedatives. Kratom also contains rhynchophylline, a non-competitive NMDA receptor antagonist. Mitragynine is metabolized in humans via phase I and phase II mechanisms with the resulting metabolites excreted in urine. In in vitro experiments, kratom extracts inhibited CYP3A4, CYP2D6, and CYP1A2 enzymes, which results in significant potential for drug interactions.
== Charity and volunteer work == In 1994, Kermani founded a language and cultural center in his parents' hometown of Isfahan, which he ran until 1997, the year the center had to close due to deteriorating German-Iranian relations. Since fall of 2014, Kermani has been serving as a patron of the initiative Willkommen für Flüchtlinge [Welcome to Refugees] via the Ehrenamt and Flüchtlinge [Volunteering and Refugees] project run by the Kölner Freiwilligenagentur [Cologne Volunteer Agency] which coordinates its offerings with the Kölner Flüchtlingsrat [Cologne Refugee Council].
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.